Cancer Immunology, Immunotherapy View Homepage


Ontology type: schema:Periodical     


Journal Info

START YEAR

1982

PUBLISHER

Springer Berlin Heidelberg

LANGUAGE

en

HOMEPAGE

http://link.springer.com/journal/262

Recent publications latest 20 shown

  • 2019-04-10 Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.
  • 2019-04-08 Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.
  • 2019-04-06 T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy.
  • 2019-04-06 Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model.
  • 2019-04-05 Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
  • 2019-04-05 Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
  • 2019-04-05 Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.
  • 2019-04-04 "Tumor Immunology Meets Oncology (TIMO) XIV", May 24-26th 2018, Halle/Saale, Germany.
  • 2019-04-03 Unlocking the therapeutic potential of primary tumor-draining lymph nodes.
  • 2019-04 Acknowledgements
  • 2019-04 Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
  • 2019-04 Interactions among myeloid regulatory cells in cancer
  • 2019-04 Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice
  • 2019-04 MDSCs in infectious diseases: regulation, roles, and readjustment
  • 2019-04 Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates
  • 2019-04 MDSC and beyond: a symposium-in-writing on myeloid cells with immunoregulatory activity by members of the Mye-EUNITER network
  • 2019-04 The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma
  • 2019-04 Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics
  • 2019-04 Role of myeloid regulatory cells (MRCs) in maintaining tissue homeostasis and promoting tolerance in autoimmunity, inflammatory disease and transplantation
  • 2019-04 A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/H33160", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Oncology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B14000", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://scigraph.springernature.com/ontologies/product-market-codes/B11001", 
            "inDefinedTermSet": "http://scigraph.springernature.com/ontologies/product-market-codes/", 
            "name": "Cancer Research", 
            "type": "DefinedTerm"
          }
        ], 
        "contentRating": [
          {
            "author": "snip", 
            "ratingValue": "0.99", 
            "type": "Rating"
          }, 
          {
            "author": "sjr", 
            "ratingValue": "1.899", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2017", 
            "ratingValue": "4.225", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "4.711", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2016", 
            "ratingValue": "4.711", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "4.846", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2015", 
            "ratingValue": "4.846", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "3.941", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2014", 
            "ratingValue": "3.941", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.943", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2013", 
            "ratingValue": "3.943", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "4.293", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2010", 
            "ratingValue": "4.293", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.791", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2009", 
            "ratingValue": "3.791", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.637", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2012", 
            "ratingValue": "3.637", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.701", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2011", 
            "ratingValue": "3.701", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.804", 
            "type": "Rating"
          }, 
          {
            "author": "impact_factor_wos", 
            "dateCreated": "2008", 
            "ratingValue": "3.804", 
            "type": "Rating"
          }
        ], 
        "description": "

    Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology.\u00a0 The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others\u2019 results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.

    In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

    • \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u201cFocussed Research Reviews,\u201d published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
    • \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u201cSymposia-in-Writing,\u201d which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

    CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and\u00a0Sociedad Espa\u00f1ola de Inmunologia-Grupo Espa\u00f1ola de\u00a0InmunoTerapia\u00a0(SEI-GEIT).

    CIMT: http://www.cimt.eu/home

    CCIC: http://www.immunotherapycancer.ca/

    JACI: http://www.jaci.jp/eng/index.html

    NIBIT: http://www.nibit.org/index.php

    SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK\u00a0\u00a0

    CITIM: http://www.canceritim.org", "editor": [ { "familyName": "Pawelec", "givenName": "Graham", "type": "Person" } ], "id": "sg:journal.1096240", "inLanguage": [ "en" ], "isAccessibleForFree": false, "issn": [ "0340-7004", "1432-0851" ], "license": "Hybrid (Open Choice)", "name": "Cancer Immunology, Immunotherapy", "productId": [ { "name": "scopus_id", "type": "PropertyValue", "value": [ "29152" ] }, { "name": "wos_id", "type": "PropertyValue", "value": [ "0340-7004/CANCER IMMUNOLOGY IMMUNOTHERAPY" ] }, { "name": "nlm_unique_id", "type": "PropertyValue", "value": [ "8605732" ] }, { "name": "nsd_ids_id", "type": "PropertyValue", "value": [ "339854" ] }, { "name": "springer_id", "type": "PropertyValue", "value": [ "262" ] }, { "name": "lccn_id", "type": "PropertyValue", "value": [ "sn 84010370" ] }, { "name": "dimensions_id", "type": "PropertyValue", "value": [ "96240" ] }, { "name": "era_ids_id", "type": "PropertyValue", "value": [ "15463" ] } ], "publisher": { "name": "Springer Berlin Heidelberg", "type": "Organization" }, "publisherImprint": "Springer", "sameAs": [ "https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240" ], "sdDataset": "journals", "sdDatePublished": "2019-03-18T11:05", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "file:///home/ubuntu/piotr/scigraph_export/journals_20190313_sn_only.jsonl", "startYear": "1982", "type": "Periodical", "url": "http://link.springer.com/journal/262" } ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/journal.1096240'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/journal.1096240'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/journal.1096240'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/journal.1096240'


     

    This table displays all metadata directly associated to this object as RDF triples.

    217 TRIPLES      21 PREDICATES      52 URIs      45 LITERALS      32 BLANK NODES

    Subject Predicate Object
    1 sg:journal.1096240 schema:about sg:ontologies/product-market-codes/B11001
    2 sg:ontologies/product-market-codes/B14000
    3 sg:ontologies/product-market-codes/H33160
    4 schema:contentRating N05cbbe622fd74c18be69d4a155c5dcce
    5 N08ddff5fdb3e46c98239ae9a023ddf63
    6 N09645766bd5d46cab57f0e8878db8c7b
    7 N151caa47797f4714adbab04d4dd734de
    8 N1e2f22e973d84ea69a8baa4aebfdfdd6
    9 N46d222214a014a4980dd09092199ee7c
    10 N4f9a46d5e1bc44b8b965a65bc1d22a4c
    11 N5775041e7b544849b58168542eb4ce08
    12 N5952aa07af8044b8b52d9e1815b93a82
    13 N5c0413d025684768bba32e043374b564
    14 N62e6a6ae196745cf86f74653d1e04370
    15 N7f89a69fdce14fb1b8567c9b34eb3ffe
    16 N81a6e947e6fd4722b7c8d9d653a0a5b9
    17 N921e0ee13fe0465c9587404827c9ab7d
    18 N964134ca213b4c89949ab7d219a9aec0
    19 Nbc8399c23d7a461281ac86f599b2de7e
    20 Nc679a0d76be14e83a63aeae561446d61
    21 Ncc4f81845dec40aebcf9d7e29631098b
    22 Ndf3735580814487395078c29fd4d5f82
    23 Ne2bc6e12aeb648e4abadb8eec6f58244
    24 Ne5f5682db83f447483472affec525a1a
    25 schema:description <p>Since its inception in 1976, <i>Cancer Immunology, Immunotherapy</i> (CII) has reported significant advances in the field of tumor immunology.  The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. </p><p>In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:</p><ul><li>         “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.</li><li>        “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.</li></ul><p>CII is affiliated with the <i>Association for Cancer Immunotherapy (CIMT)</i>,<i> Canadian Cancer Immunotherapy Consortium (CCIC)</i>, <i>The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT</i>),<i> </i>and <i>Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT)</i>.</p><p>CIMT: http://www.cimt.eu/home</p><p>CCIC: http://www.immunotherapycancer.ca/</p><p>JACI: http://www.jaci.jp/eng/index.html</p><p>NIBIT: http://www.nibit.org/index.php</p><p>SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&amp;Upfqym5uom=GK  </p>CITIM: http://www.canceritim.org
    26 schema:editor N380771a17aeb4d828b24dbd2792d9e2a
    27 schema:inLanguage en
    28 schema:isAccessibleForFree false
    29 schema:issn 0340-7004
    30 1432-0851
    31 schema:license Hybrid (Open Choice)
    32 schema:name Cancer Immunology, Immunotherapy
    33 schema:productId N1bc67f6c113740288ce46ef0bac4d939
    34 N992ad45592c248cf809dfd3ddcececa2
    35 Na3a9bf7ae72a41e4b5fc6d73dfed4990
    36 Nd360213de66b4c9ba65fdec5929ef66c
    37 Ndc60ee4ca35b4dbdb6a4fff6ab581fcf
    38 Ndd720c2e89b5436c930437f894a5c8ab
    39 Necade19b536b420283c7fa3fdc3dbf19
    40 Nf666833d31b745648be16d3a37d205db
    41 schema:publisher N04de6cac3148465ea9cb9aa9c8465e25
    42 schema:publisherImprint Springer
    43 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_source_title=jour.1096240
    44 schema:sdDatePublished 2019-03-18T11:05
    45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    46 schema:sdPublisher N5e7f6036cd8a404cb53c0520cfb7b806
    47 schema:startYear 1982
    48 schema:url http://link.springer.com/journal/262
    49 sgo:license sg:explorer/license/
    50 sgo:sdDataset journals
    51 rdf:type schema:Periodical
    52 N04de6cac3148465ea9cb9aa9c8465e25 schema:name Springer Berlin Heidelberg
    53 rdf:type schema:Organization
    54 N05cbbe622fd74c18be69d4a155c5dcce schema:author N419afeb4169d4ebea4463b5aeaabc0a2
    55 schema:dateCreated 2012
    56 schema:ratingValue 3.637
    57 rdf:type schema:Rating
    58 N08ddff5fdb3e46c98239ae9a023ddf63 schema:author N2b27c11739814bc3884252c394d7d55f
    59 schema:dateCreated 2014
    60 schema:ratingValue 3.941
    61 rdf:type schema:Rating
    62 N09645766bd5d46cab57f0e8878db8c7b schema:author N1f021ced265448648bd883c1a720870a
    63 schema:ratingValue 1.899
    64 rdf:type schema:Rating
    65 N151caa47797f4714adbab04d4dd734de schema:author N9eb158a2bdbd4b5d99c42fa7c6bd0abd
    66 schema:ratingValue 0.99
    67 rdf:type schema:Rating
    68 N1bc67f6c113740288ce46ef0bac4d939 schema:name lccn_id
    69 schema:value sn 84010370
    70 rdf:type schema:PropertyValue
    71 N1e2f22e973d84ea69a8baa4aebfdfdd6 schema:author N5a7bf108c4d1443f873fc9bec0018ad5
    72 schema:dateCreated 2009
    73 schema:ratingValue 3.791
    74 rdf:type schema:Rating
    75 N1f021ced265448648bd883c1a720870a rdf:first sjr
    76 rdf:rest rdf:nil
    77 N2b188cf28be64bd1be95db03755d7a4a rdf:first impact_factor_wos
    78 rdf:rest rdf:nil
    79 N2b27c11739814bc3884252c394d7d55f rdf:first impact_factor_wos
    80 rdf:rest rdf:nil
    81 N2d15046d7bfa47f6ac2608c1aa400624 rdf:first impact_factor_wos
    82 rdf:rest rdf:nil
    83 N380771a17aeb4d828b24dbd2792d9e2a rdf:first N8721d0d0f71a439e8e17b066e766c5f4
    84 rdf:rest rdf:nil
    85 N3b0296a2adca4f2883e5692e70650aa7 rdf:first impact_factor_wos
    86 rdf:rest rdf:nil
    87 N419afeb4169d4ebea4463b5aeaabc0a2 rdf:first impact_factor_wos
    88 rdf:rest rdf:nil
    89 N46d222214a014a4980dd09092199ee7c schema:author Nb6defbc3804e46d3b8f6731d102f2d41
    90 schema:dateCreated 2013
    91 schema:ratingValue 3.943
    92 rdf:type schema:Rating
    93 N493f99e5f1ec4ddc8996e5dec83b1e2d rdf:first impact_factor_wos
    94 rdf:rest rdf:nil
    95 N4f9a46d5e1bc44b8b965a65bc1d22a4c schema:author Nc5e4c2114e114305b70efa1e96785e28
    96 schema:dateCreated 2014
    97 schema:ratingValue 3.941
    98 rdf:type schema:Rating
    99 N5041fd066496420990bd364885638f91 rdf:first impact_factor_wos
    100 rdf:rest rdf:nil
    101 N5064d7c429f245debcab6f5e74a153cd rdf:first impact_factor_wos
    102 rdf:rest rdf:nil
    103 N5775041e7b544849b58168542eb4ce08 schema:author N5064d7c429f245debcab6f5e74a153cd
    104 schema:dateCreated 2015
    105 schema:ratingValue 4.846
    106 rdf:type schema:Rating
    107 N5952aa07af8044b8b52d9e1815b93a82 schema:author Nc15016732cb14916a0cf0b3503494f1a
    108 schema:dateCreated 2010
    109 schema:ratingValue 4.293
    110 rdf:type schema:Rating
    111 N5a7bf108c4d1443f873fc9bec0018ad5 rdf:first impact_factor_wos
    112 rdf:rest rdf:nil
    113 N5c0413d025684768bba32e043374b564 schema:author N907ed92ada034549b5f6e7d1b7492da5
    114 schema:dateCreated 2016
    115 schema:ratingValue 4.711
    116 rdf:type schema:Rating
    117 N5e7f6036cd8a404cb53c0520cfb7b806 schema:name Springer Nature - SN SciGraph project
    118 rdf:type schema:Organization
    119 N62e6a6ae196745cf86f74653d1e04370 schema:author N2b188cf28be64bd1be95db03755d7a4a
    120 schema:dateCreated 2012
    121 schema:ratingValue 3.637
    122 rdf:type schema:Rating
    123 N6d116fd71a854e028ea0e1716e242f4b rdf:first impact_factor_wos
    124 rdf:rest rdf:nil
    125 N7b7fcd4620e94794bbb795fd875c9824 rdf:first impact_factor_wos
    126 rdf:rest rdf:nil
    127 N7c90b34873e6415a89e4e59ee427cfe0 rdf:first impact_factor_wos
    128 rdf:rest rdf:nil
    129 N7f89a69fdce14fb1b8567c9b34eb3ffe schema:author Nc09a1b77cd4c4dc5b48f608b1d50540a
    130 schema:dateCreated 2010
    131 schema:ratingValue 4.293
    132 rdf:type schema:Rating
    133 N81a6e947e6fd4722b7c8d9d653a0a5b9 schema:author N7c90b34873e6415a89e4e59ee427cfe0
    134 schema:dateCreated 2015
    135 schema:ratingValue 4.846
    136 rdf:type schema:Rating
    137 N8721d0d0f71a439e8e17b066e766c5f4 schema:familyName Pawelec
    138 schema:givenName Graham
    139 rdf:type schema:Person
    140 N8a8e8503d1004bbba21dbee724b6eeec rdf:first impact_factor_wos
    141 rdf:rest rdf:nil
    142 N907ed92ada034549b5f6e7d1b7492da5 rdf:first impact_factor_wos
    143 rdf:rest rdf:nil
    144 N921e0ee13fe0465c9587404827c9ab7d schema:author N7b7fcd4620e94794bbb795fd875c9824
    145 schema:dateCreated 2008
    146 schema:ratingValue 3.804
    147 rdf:type schema:Rating
    148 N964134ca213b4c89949ab7d219a9aec0 schema:author N6d116fd71a854e028ea0e1716e242f4b
    149 schema:dateCreated 2008
    150 schema:ratingValue 3.804
    151 rdf:type schema:Rating
    152 N96a6fbb8bade4e90b8b58cf9a60ff2fa rdf:first impact_factor_wos
    153 rdf:rest rdf:nil
    154 N992ad45592c248cf809dfd3ddcececa2 schema:name wos_id
    155 schema:value 0340-7004/CANCER IMMUNOLOGY IMMUNOTHERAPY
    156 rdf:type schema:PropertyValue
    157 N9eb158a2bdbd4b5d99c42fa7c6bd0abd rdf:first snip
    158 rdf:rest rdf:nil
    159 Na3a9bf7ae72a41e4b5fc6d73dfed4990 schema:name dimensions_id
    160 schema:value 96240
    161 rdf:type schema:PropertyValue
    162 Nb6defbc3804e46d3b8f6731d102f2d41 rdf:first impact_factor_wos
    163 rdf:rest rdf:nil
    164 Nbc8399c23d7a461281ac86f599b2de7e schema:author N3b0296a2adca4f2883e5692e70650aa7
    165 schema:dateCreated 2009
    166 schema:ratingValue 3.791
    167 rdf:type schema:Rating
    168 Nc09a1b77cd4c4dc5b48f608b1d50540a rdf:first impact_factor_wos
    169 rdf:rest rdf:nil
    170 Nc15016732cb14916a0cf0b3503494f1a rdf:first impact_factor_wos
    171 rdf:rest rdf:nil
    172 Nc5e4c2114e114305b70efa1e96785e28 rdf:first impact_factor_wos
    173 rdf:rest rdf:nil
    174 Nc679a0d76be14e83a63aeae561446d61 schema:author N2d15046d7bfa47f6ac2608c1aa400624
    175 schema:dateCreated 2011
    176 schema:ratingValue 3.701
    177 rdf:type schema:Rating
    178 Ncc4f81845dec40aebcf9d7e29631098b schema:author N96a6fbb8bade4e90b8b58cf9a60ff2fa
    179 schema:dateCreated 2016
    180 schema:ratingValue 4.711
    181 rdf:type schema:Rating
    182 Nd360213de66b4c9ba65fdec5929ef66c schema:name era_ids_id
    183 schema:value 15463
    184 rdf:type schema:PropertyValue
    185 Ndc60ee4ca35b4dbdb6a4fff6ab581fcf schema:name nsd_ids_id
    186 schema:value 339854
    187 rdf:type schema:PropertyValue
    188 Ndd720c2e89b5436c930437f894a5c8ab schema:name scopus_id
    189 schema:value 29152
    190 rdf:type schema:PropertyValue
    191 Ndf3735580814487395078c29fd4d5f82 schema:author N8a8e8503d1004bbba21dbee724b6eeec
    192 schema:dateCreated 2011
    193 schema:ratingValue 3.701
    194 rdf:type schema:Rating
    195 Ne2bc6e12aeb648e4abadb8eec6f58244 schema:author N5041fd066496420990bd364885638f91
    196 schema:dateCreated 2017
    197 schema:ratingValue 4.225
    198 rdf:type schema:Rating
    199 Ne5f5682db83f447483472affec525a1a schema:author N493f99e5f1ec4ddc8996e5dec83b1e2d
    200 schema:dateCreated 2013
    201 schema:ratingValue 3.943
    202 rdf:type schema:Rating
    203 Necade19b536b420283c7fa3fdc3dbf19 schema:name nlm_unique_id
    204 schema:value 8605732
    205 rdf:type schema:PropertyValue
    206 Nf666833d31b745648be16d3a37d205db schema:name springer_id
    207 schema:value 262
    208 rdf:type schema:PropertyValue
    209 sg:ontologies/product-market-codes/B11001 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    210 schema:name Cancer Research
    211 rdf:type schema:DefinedTerm
    212 sg:ontologies/product-market-codes/B14000 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    213 schema:name Immunology
    214 rdf:type schema:DefinedTerm
    215 sg:ontologies/product-market-codes/H33160 schema:inDefinedTermSet sg:ontologies/product-market-codes/
    216 schema:name Oncology
    217 rdf:type schema:DefinedTerm
     




    Preview window. Press ESC to close (or click here)


    ...